Status:
UNKNOWN
SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Lead Sponsor:
Sohag University
Conditions:
Urinary Bladder Neoplasm
Eligibility:
All Genders
Brief Summary
Bladder carcinoma (BC) is the 13th leading cause of cancer mortality worldwide . In Egypt, BC is the third common malignant tumor. Its incidence is 8.7% of all malignant tumors in both sexes with more...
Eligibility Criteria
Inclusion
- Patient with urinary bladder carcinoma.
- Specimen with submitted muscle layer
Exclusion
- Patients with insufficient clinical data.
- Patients with recurrence of the primary tumor.
- Specimens with extensive necrosis
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05429710
Start Date
October 1 2022
End Date
December 1 2023
Last Update
June 23 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.